Since infigratinib has been approved for the treatment of cholangiocarcinoma patients with FGFR2 gene mutations, cholangiocarcinoma patients who receives this combination therapy may benefit from the inhibition of tumour cell growth and lymphangiogenesis, although more experiments and clinical trials are required to verify our hypothesis. This evidence concerns the gene FGFR2 and cholangiocarcinoma.